Navigation Links
Organovo Announces Relocation and Commencement of Operations at Larger Facility
Date:7/17/2012

SAN DIEGO, July 17, 2012 /PRNewswire/ -- Organovo Holdings, Inc. (OTCQB: ONVO), a biotechnology company focused on delivering breakthrough three-dimensional (3D) bioprinting technology, today announced a facility relocation and expansion.  Organovo has moved its headquarters to a new 15,539 sq ft facility in San Diego, California. The facility consists of mixed lab and office space and features a clean room space nearly four times larger than Organovo's previous facility.  Clean room facilities are required for protection of the functional human tissues created by Organovo's innovative 3D bioprinting process.

The space is located in the Portola development in the Sorrento Mesa area of San Diego. Alexandria Real Estate is the property owner and manager through its regional LLC.  Cushman and Wakefield, LLC brokered the transaction, with Brent Jacobs and Greg Bisconti of the life sciences group representing Organovo. Organovo's previous headquarters facility consisted of 4,432 sq ft of mixed office and lab space. In the expanded facility, Organovo will continue its focus on developing bioprinting to create a broad array of functional 3D tissues that can recapitulate in vivo biology for human disease research, drug discovery and development, toxicology testing and, eventually, as therapies.

"Organovo's facility expansion provides a state-of-the-art space for our team to drive innovation with our research and development initiatives and supports partnering activities with our bioprinting technologies," commented Keith Murphy, chairman and chief executive officer of Organovo.  "We now have the space to expand our expertise into additional areas of research and development and to expand our bioprinting capacity with up to four NovoGen MMX Bioprinters in regular operation. The new facility provides essential resources for Organovo to advance the development of new bioprinter technologies, 3D
'/>"/>

SOURCE Organovo Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications
2. Organovo, Inc. Investor Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com
3. Organovo, Inc. to Webcast, Live, at RetailInvestorConferences.com on March 1st
4. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
5. BioStorage Technologies Continues Global Growth; Announces Strategic Expansion Into Asia Pacific and New General Manager APAC
6. Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
7. GenoSpace Announces the Launch of a Cloud-Based "Information Ecosystem" for Advancing 21st-Century Personalized Medicine
8. Inclinix-PMG Holdings, Inc. Announces Executive Management Changes
9. MetaStat, Inc. Announces Allowance of Patent Claims
10. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
11. PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015 ... the addition of the "Global PDT Machine ...        (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... 2014 is a professional and in-depth study on ... ,The report provides a basic overview of the ...
(Date:6/1/2015)... Grove, IL (PRWEB) June 01, 2015 ... in developing and manufacturing of chiral stationary phases ... the options for its current and presenting solutions ... Service to its portfolio. This valuable addition to ... fast and effective advantage that can tackle projects ...
(Date:6/1/2015)... 1, 2015  Fennec Pharmaceuticals, Inc. (TSX: FRX, ... results from a poster presented today entitled, "Anti-tumor ... phase III trial of the efficacy of sodium ... cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB)." ... of Clinical Oncology (ASCO) 2015 Annual Meeting in ...
(Date:6/1/2015)... LANSING, Mich. , June 1, 2015  Neogen Corporation ... the assets of Sterling Test House, a leading commercial food ... and that the acquired laboratory will serve as a base ... . Sterling Test House was ... virtually all of the food safety and water quality testing ...
Breaking Biology Technology:Global PDT Machine Industry Report 2014 2Regis Technologies Offers Chiral Chromatography Service 2Regis Technologies Offers Chiral Chromatography Service 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4Neogen acquires India food safety company 2
... Calif., April 21 /PRNewswire-FirstCall/-- Pharmacyclics,Inc. (Nasdaq: PCYC ... staff,deficiency letter on April 17, 2008 indicating that, ... for Pharmacyclics, common stock has closed,below the minimum ... for continued,inclusion on The Nasdaq Global Market under ...
... Per Share, SAN JOSE, Calif., April 21 ... provider of medical devices,for the minimally invasive treatment of ... quarter ended March 31, 2008., Net revenues for ... compared with $15.6 million for the first quarter of ...
... CALL AND WEBCAST SCHEDULED FOR WEDNESDAY, APRIL 30, ... NBIX ) announced today that the Company will report ... closes on Wednesday,April 30, 2008. Neurocrine will host a ... and provide a Company update Wednesday,afternoon, April 30, 2008 ...
Cached Biology Technology:VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 2VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 3VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 4VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 5VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 6VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 7Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results 2
(Date:5/27/2015)... , May 27, 2015   ... medication safety systems and image documentation solutions ... of comprehensive, technologically-advanced automation solutions, is pleased ... integration. The Codonics® Safe Label System® (SLS), ... in conjunction with the Omnicell Anesthesia Workstation, ...
(Date:5/22/2015)... , May 22, 2015 According ... by Solution (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, ... (Government and Utilities, Consumer and Home) - Global Forecast ... grow from $2.77 Billion in 2015 to $6.19 Billion ... Browse 79 market data Tables and   43 ...
(Date:5/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... LLC, a company engaged in biometric identification is an ... portion of the recently awarded TIES (Technical Information Engineering ... Army. 3D-ID LLC has a suite of ... and security agencies. Gino Pereira , ...
Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... issue of Nature Genetics, is based on data from ... known genes, but also discovered ten new genes. Altogether ... 3.5 centimeters. The analysis produced some biologically insightful ... the microRNA let-7, which affects the regulation of other ...
... May 2008 Pediatric Academic Societies and Asian Society for ... obesity negatively impacts vascular endothelial function, which relates to ... the U.S. during the past 20 years and obesity ... incidence of obesity in children is also increasing and ...
... has swapped their comfortable offices for one of the ... a challenging field campaign that is seen as the ... mission CryoSat will be as accurate as possible. ... are currently in the middle of CryoSat Validation Experiment ...
Cached Biology News:How body size is regulated 2Study supports reason for concern in childhood and adolescent obesity 2Scientists endure Arctic for last campaign prior to CryoSat-2 launch 2Scientists endure Arctic for last campaign prior to CryoSat-2 launch 3
... (IC50 = 59.2 M). Formula: ... O 13 MolWeight: ... RT CAS: ... to 100 mM in DMSO IUPAC: ...
POU domain, class 2, transcription factor 2,...
NAP-2 (5C7)...
IKKbeta/IKK-2 Polyclonal Antibody 100 ug affinity purified rabbit polyclonal antibody. Reacts with human. Tested in Western blotting....
Biology Products: